EcoDrugPlus

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSUPAG00010019305
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSUPAG00010011539
Gene Symbol: ADAM17
3 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSUPAG00010003407
Gene Symbol: ADAMTS5
3 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSUPAG00010008614
Gene Symbol: ADRM1
3 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSUPAG00010018628
Gene Symbol: AKT1
1 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSUPAG00010022539
Gene Symbol: AKT2
1 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSUPAG00010018428
Gene Symbol: AKT3
1 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSUPAG00010002138
Gene Symbol: ALK
1 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSUPAG00010017239
Gene Symbol: ABCB1
3 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSUPAG00010022634
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSUPAG00010006784
Gene Symbol: ABCC8
1 Cross references
237 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSUPAG00010017855
Gene Symbol: ABCC9
3 Cross references
232 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).